Please assess the completion status of the following clinical trial:

Trial Title: Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. acute ischemic stroke~2. age 18 to 83 years If \>80 then the pre-stroke mRS needs to be \< 1)~3. Right hemisphere NIHSS 6 -15, left hemisphere NIHSS 6-18~4. known onset time of acute symptoms~5. stem cell transplantation procedure must be performed within 24 to 72 hrs after stroke symptom onset~6. TPA infusion is allowed~Exclusion Criteria:~1. NIHSS 1a \> 1~2. pre-stroke mRS \> 1 if \> 80 years of age~3. Ischemic stroke in the last 3 months, any vascular territory~4. MI, primary hemorrhagic or traumatic lesion of the brain within the last 3 months or identified on MRI. Small hemorrhagic transformation of the acute infarct is allowed.~5. seizure disorder~6. developmental delay~7. chronic kidney disease defined as baseline creatinine \>1.4~8. hepatic disease or altered liver function as defined by SGPT \>150 U/L and or T. Bilirubin \>1.6 mg/dL at admission~9. pulmonary disease (e.g, COPD with oxygen-requirement at rest or with ambulation, moderate to severe asthma)~10. mechanical heart valve~11. Active malignancy or diagnosis of malignancy within 5 years prior to the start of screening or any history of chemotherapy or radiation affecting the bone marrow. Skin cancers (except for melanoma) are permitted.~12. prior immunosuppression, including chemotherapy administration within last 3 years or current immunosuppression as defined by WBC \<3 x 103 cells/ml~13. known HIV~14. hemoglobin \<10g/dl~15. uncorrected coagulopathy at the time of consent defined as INR \>1.4; PTT\>37 sec, or thrombocytopenia (PLT\<100,000)~16. any hemodynamic instability at the time of consent (e.g, requiring continuous fluid resuscitation or ionotropic support).~17. Hypoxemia (SaO2\<90%) at the time of consent, respiratory distress or persistent hypoxemia defined as SaO2 \<94% for \>30 minutes occurring at any time from hospital admission to time of consent. Intubation alone is not an exclusion.~18. pregnancy or positive b-HCG~19. current participation in any interventional research study~20. unable to return for follow-up visits for clinical evaluation, laboratory studies, or imaging evaluation~21. Multiple anti-platelet medications (Aggrenox is considered a single platelet agent)~22. Unable to undergo MRI or CT scan~23. Any other condition that the investigator feels would pose a significant hazard to the patient if enrolled.~24. Exclude infarct lesion size \>145cc unless the NIHSS 1a remains \< 1 and there is no evidence of infarct expansion or edema formation on any imaging obtained from admission up to the point just prior to infusion.~25. Exclude IA therapy use or if there is a planned or anticipated hemicraniectomy. Diagnostic angiograms are allowed~26. CT and/or Multimodal MRI exclusion criteria will be:~    * hemispheric strokes \< 1.5 cm maximum diameter (on the MRI as seen on the diffusion-weighted imaging or CT)~   * midline shift \>1mm or significant hemorrhagic transformation of the acute infarct

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 83 Years
- Healthy Volunteers: f

Study Arms:
- Autologous Bone Marrow Mononuclear Cells (Type: EXPERIMENTAL): Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete